Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results

November 3, 2014

BURLINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the third quarter and the year to date period ending September 30, 2014 on Monday, November 10, 2014, prior to the market open.

Aldeyra will hold a conference call on Monday, November 10, 2014, at 8:30 a.m. ET. Dr. Todd Brady, President and Chief Executive Officer, and Stephen Tulipano, Chief Financial Officer, will host the conference call to discuss Aldeyra's financial results for the third quarter and the year to date period ending September 30, 2014 and provide a general business update. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13593796. A live webcast of the conference call will also be available on the investor relations page of Aldeyra's corporate website at www.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra's website for one year. In addition, a telephonic replay of the call will be available until November 24, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13593796.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2 and other related compounds, designed to trap free aldehydes. Aldeyra plans to file Investigational New Drug (IND) applications for clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

CONTACT: Corporate Contact:

         Stephen TulipanoAldeyra Therapeutics, Inc.

         Tel: +1 781-761-4904 ext. 205

         Or +1 617-308-2374

         stulipano@aldeyra.com



         Investor Contact:

         David Burke/Lee RothThe Ruth Group

         Tel: +1 646-536-7009/7012

         dburke@theruthgroup.com/lroth@theruthgroup.com
Source: Aldeyra Therapeutics

News Provided by Acquire Media

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video